FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
--	--

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APP	ROVAL
/B Number:	3235-0287

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Name and Address of Reporting Person [*] MUELLER PETER (Last) (First) (Middle)	2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) below)			
C/O VERTEX PHARMACEUTICALS INCORPORATED	3. Date of Earliest Transaction (Month/Day/Year) 05/15/2012	EVP, Global R&D, CSO			
130 WAVERLY ST Street) CAMBRIDGE MA 02139 (City) (State) (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person			

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)					5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1150.4)
Common Stock	05/15/2012		М		6,500	A	\$16.32	138,816	D	
Common Stock	05/15/2012		S ⁽¹⁾		2,100	D	\$63.84 ⁽²⁾⁽³⁾	136,716	D	
Common Stock	05/15/2012		S ⁽¹⁾		3,700	D	\$64.3 ⁽³⁾⁽⁴⁾	133,016	D	
Common Stock	05/15/2012		S ⁽¹⁾		700	D	\$ 65.5 ⁽³⁾⁽⁵⁾	132,316	D	
Common Stock								4,367	I	401(k)
Common Stock								15,920	I	Common Stock held in trust. ⁽⁶⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Expiration Date Derivative (Month/Day/Year) Securities Acquired		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option	\$16.32	05/15/2012		М			6,500	10/15/2003	07/14/2013	Common Stock	6,500	\$0.00	42,300	D	

Explanation of Responses:

1. Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1.

2. Open market sales reported on this line occurred at a weighted average price of \$63.84 (range \$63.63 to \$63.99).

3. Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

4. Open market sales reported on this line occurred at a weighted average price of \$64.30 (range \$64.01 to \$64.85).

5. Open market sales reported on this line occurred at a weighted average price of \$65.50 (range \$65.00 to \$65.93).

6. Common stock held in grantor retained annuity trusts.

Remarks:

David T. Howton, Attorney-In-05/16/2012

<u>Fact</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.